TABLE 2

Characteristics of Patients with Relapse and with Poor Prognostic Features vs. Comparative ¹⁸F-FDG PET Results

Patient no.	Age (y)	Histology	Ann Arbor stage	Tumor size	After 1 cycle	After completion	Outcome	PFS (mo)
1	>60	DLCL	IIIB	Bulky	+	− (FN)	Relapse	18
2	>60	DLCL	IIA	Nonbulky	+	− (FN)	Relapse	10
3	<60	DLCL	IIB	Bulky	+	− (FN)	Relapse	6
4	>60	FLC	IIIA	Bulky	−	−	Remission	24
5	<60	HD	IIB	Bulky	+ (FP)	+ (FP)	Remission	18
6	<60	HD	IIA	Bulky	−	−	Remission	20
7	>60	DLCL	IIA	Bulky	−	−	Remission	19
8	>60	FLC	IV	Nonbulky	−	−	Remission	20
9		DLCL			+	− (FN)	Relapse	7
10		DLCL			+	+	NFOD	0
11		HD			− (FN)	+	Relapse	4
12		LL			+	+	NFOD	0
13		HD			+	− (FN)	Relapse	5
14		DLCL			+	+	NFOD	0
15		DLCL			− (FN)	− (FN)	Relapse	6
16		DLCL			−	−	Remission	18
17		HD			+	+	NFOD	0
18		DLCL			−	−	Remission	18

After 1 cycle = ¹⁸F-FDG PET after first cycle of chemotherapy; After completion = ¹⁸F-FDG PET after completion of chemotherapy; DLCL = diffuse large cell lymphoma; FN = false-negative; FLC = follicular large cell lymphoma; FP = false-positive; NFOD = never free of disease; LL = lymphoblastic lymphoma.
Patients 1–8 had poor prognostic features at initial staging; patients 9–18 were included in study at relapse.